NCT04071639

Symptomatic Therapy for Patients With Huntington's Disease

Non-randomized Control Clinical Trial to Evaluate the Efficacy and Safety of Symptomatic Drug Therapy for Mild to Moderate Huntington's Disease Patients

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

Based on the previous symptomatic treatment of Chinese HD patients, this study intends to further optimize the treatment regimen of Chinese HD patients so as to further improve the prognosis of patients.

Detailed description

The purpose of the study is to evaluate symptomatic treatment regimen efficacy based on different disease stages. We previously used symptomatic treatment on Chinese HD patients and most of them got improved both in the motor symptoms and life quality. So this study intends to further optimize the treatment regimen, and set a control group to further evaluate the treatment efficacy.

Conditions

• Huntington Disease

Interventions

Type	Name	Description
DRUG	Haloperidol 2Mg Tab	Haloperidol take 0.5mg\~2mg three time a day.
DRUG	Risperidone 1Mg Tab	Risperidone take 1mg once at night.
DRUG	Zoloft 50Mg Tablet	Zoloft take 50mg once in the morning.
DRUG	Idebenone	Idebebone take 30mg three times a day.
DRUG	Deutetrabenazine Oral Tablet [Austedo]	The recommended starting dose of Austedo is 6 mg administered orally once daily, and dose may be increased at weekly intervals in increments of 6 mg per day to a maximum recommended daily dosage of 48 mg.

Timeline

• Start date: 2020-03-12
• Primary completion: 2024-12-31
• Completion: 2024-12-31
• First posted: 2019-08-28
• Last updated: 2021-04-02

Locations

1 site across 1 country: China